Today is National #WearRedDay, a day dedicated to raising awareness about #heartdisease, particularly in women. While we’re wearing red today in support of this cause, we’re also brushing up on just how many women heart disease impacts. Test your knowledge with us below! #AmericanHeartMonth How many women in the U.S. live with heart disease?

Our ultimate goal in protecting the world from cardiovascular disease is bringing low-density lipoprotein cholesterol (LDL-C), or “bad cholesterol”, levels as low as possible for as long as possible. This is because elevated LDL-C levels increase the risk of early-onset atherosclerotic #cardiovascular disease (ASCVD). In this next segment of #VerveVocab, learn all about #LDLC from Steve Richards, Allison Dorval, Victoria Bartlett, and why it’s a crucial part of our approach to treating #heartdisease.

Join our co-founder and CEO @skathire for a live fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York. Please visit the investor section of our website to register. An archive of the webcast will be available for 90 days following the presentation.

As we step into 2025, @skathire reflects on Verve’s progress from 2024 and forecasts what’s ahead for Verve in 2025, including key data readouts and the initiation of a Phase 2 clinical trial for VERVE-102. #JPM25

Are you ready for #JPM25? Our founder and CEO @skathire, will be presenting on Wednesday, January 15 at 11:15 a.m. PT to provide a summary of our achievements in 2024 and outline upcoming milestones for 2025.

We couldn’t help but close out the year with one more company gathering, this time with milk and cookies in hand and plenty of holiday cheer. We’re thankful for the closeness of our team and for another year of great progress toward our goal of providing meaningful treatments for #cardiovascular disease. From all of us at Verve, happy holidays, and we will see you in 2025!

We have been recognized by the @BostonGlobe as a top place to work in Massachusetts for the fourth year in a row and placed #6 among large companies for 2024. We’re passionate about building a workplace where innovation, collaboration, and purpose thrive, and are thankful for all Vervians for making our company such a special place to work. Here's to another year of making a difference in the cardiovascular community together.

Lowering your LDL-cholesterol (LDL-C) level early and maintaining it long-term can slow atherosclerosis progression and significantly reduce the lifetime risk of atherosclerosis and #cardiovascular disease (ASCVD). Verve’s approach – a single treatment designed to provide lifelong LDL-C lowering – seeks to disrupt the current chronic care model for treating patients living with this life-threatening disease. Learn more about how reducing cumulative exposure to LDL-cholesterol slows the progression of atherosclerotic cardiovascular events in this recent article from Verve’s Scientific Advisory Board Chair Dr. Eugene Braunwald in @NaturePortfolio Review Cardiology:

VERVE-102 is currently being evaluated in our Heart-2 Phase 1b clinical trial in patients with premature coronary artery disease (CAD) and heterozygous familial hypercholesterolemia (HeFH). What is premature CAD? Click through to fuel your curiosity. (2/2)

We recently reported updated durability data from the Heart-1 clinical trial of VERVE-101 at #ESGCT. In the single participant in the highest dose cohort, LDL-C reduction has been sustained out to 18 months after the single dose. These new durability data further support the potential of once-and-done #geneediting medicines for the treatment of #cardiovascular disease. Click here to see the presentation from ESGCT:

We look forward to participating in the @American_Heart’s Scientific Sessions this week! Our VP, Translational Medicine will be in Chicago speaking to our Heart-2 clinical trial design and our approach to targeting PCSK9 as part of the Genomic Therapies for Cardiovascular Diseases session. Read more about #AHA24 here:

In honor of #STEMDay, we’re celebrating the innovators and leaders driving progress in science, technology, engineering, and math. We’re proud to be part of an industry committed to advancing science and the healthcare industry as a whole. We asked members of our team to share their thoughts on what drew them to STEM and the importance of STEM research. Their insights reflect the dedication that fuels our mission to make a meaningful impact in #cardiovascular health.

We look forward to participating in fireside chats during Guggenheim's Inaugural Healthcare Innovation Conference, Stifel’s 2024 Healthcare Conference, and the #JefferiesHealthcare Conference this month. See the full details below.

Today, we announced pipeline progress and earnings from Q3 2024. Check out our latest updates: 👉 The Heart-2 Phase 1b clinical trial of VERVE-102 is ongoing, and as of October 30, 2024, seven participants have been dosed. VERVE-102 has been well-tolerated. No serious adverse events and no clinically significant laboratory abnormalities have been observed. 👉 We expect to provide initial data from the Heart-2 clinical trial in the first half of 2025. 👉 The first participant was dosed in the Pulse-1 Phase 1b clinical trial, evaluating VERVE-201 for HeFH and refractory hypercholesterolemia. 👉 Strong cash position and runway expected through 2026. Read the full announcement here:

Another year, another successful @American_Heart #HeartWalk in Boston! ❤️ With 137 walkers across 10 teams, we’re proud to have reached our fundraising goal, contributing toward Boston’s overall goal of $1.2 million to improve health and help significantly reduce #heartdisease and stroke death rates. Learn more about this important initiative here:

Our co-founder and CEO @skathire will participate in a plenary session at the @ASNKidney #KidneyWk in San Diego and speak to the development of #geneediting medicines for #cardiovascular health. If you’re attending, catch the presentation at 9 a.m. on October 25, and learn more about the session here:

Our Vice President of Genomic Medicine @amitvkhera will be presenting at this year’s #ESGCT Annual Congress in Rome. He will discuss Verve’s mission of developing single-course #geneediting medicines to help treat patients living with #cardiovascular disease. Read more about the event here: